INVENTIVA Stock 13.4% Up Today

(VIANEWS) – The Market ended the session with INVENTIVA (IVA.PA) rising 13.4% to €2.84 on Monday while CAC 40 fell 0.21% to €7,303.81.

About INVENTIVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Earnings Per Share

As for profitability, INVENTIVA has a trailing twelve months EPS of €-1.2.

More news about INVENTIVA (IVA.PA).

Leave a Reply

Your email address will not be published. Required fields are marked *